Macquarie Group Ltd. increased its position in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) by 20.0% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 2,268,691 shares of the biopharmaceutical company’s stock after acquiring an additional 378,606 shares during the period. Macquarie Group Ltd. owned about 5.05% of Vanda Pharmaceuticals worth $34,484,000 at the end of the most recent reporting period.
Several other institutional investors and hedge funds have also recently modified their holdings of the stock. BlackRock Inc. grew its holdings in shares of Vanda Pharmaceuticals by 2.4% in the fourth quarter. BlackRock Inc. now owns 4,568,159 shares of the biopharmaceutical company’s stock worth $69,436,000 after acquiring an additional 106,228 shares during the period. Armistice Capital LLC grew its holdings in shares of Vanda Pharmaceuticals by 74.8% in the fourth quarter. Armistice Capital LLC now owns 2,678,000 shares of the biopharmaceutical company’s stock worth $40,706,000 after acquiring an additional 1,146,000 shares during the period. Renaissance Technologies LLC grew its holdings in shares of Vanda Pharmaceuticals by 17.8% in the fourth quarter. Renaissance Technologies LLC now owns 1,434,850 shares of the biopharmaceutical company’s stock worth $21,810,000 after acquiring an additional 216,600 shares during the period. Rothschild Asset Management Inc. bought a new stake in shares of Vanda Pharmaceuticals in the third quarter worth $23,491,000. Finally, Stonepine Capital Management LLC grew its holdings in shares of Vanda Pharmaceuticals by 195.0% in the fourth quarter. Stonepine Capital Management LLC now owns 885,000 shares of the biopharmaceutical company’s stock worth $13,452,000 after acquiring an additional 585,000 shares during the period. 89.96% of the stock is owned by institutional investors.
Several analysts have issued reports on the company. Seaport Global Securities reissued a “buy” rating and set a $21.00 price target on shares of Vanda Pharmaceuticals in a report on Wednesday, February 28th. BidaskClub raised Vanda Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Wednesday, February 21st. Oppenheimer set a $27.00 price target on Vanda Pharmaceuticals and gave the company a “buy” rating in a report on Monday, March 5th. Jefferies Group reissued a “buy” rating and set a $20.00 price target on shares of Vanda Pharmaceuticals in a report on Tuesday, February 13th. Finally, ValuEngine raised Vanda Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Wednesday, December 20th. Two investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. The stock has an average rating of “Buy” and an average price target of $21.57.
VNDA stock opened at $16.90 on Wednesday. The firm has a market capitalization of $859.97, a PE ratio of -49.70 and a beta of 1.02. Vanda Pharmaceuticals Inc. has a one year low of $11.90 and a one year high of $20.40.
Vanda Pharmaceuticals (NASDAQ:VNDA) last released its quarterly earnings data on Wednesday, February 14th. The biopharmaceutical company reported ($0.04) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.12) by $0.08. The firm had revenue of $44.28 million during the quarter, compared to analyst estimates of $44.00 million. Vanda Pharmaceuticals had a negative return on equity of 11.94% and a negative net margin of 9.43%. The business’s quarterly revenue was up 15.8% compared to the same quarter last year. During the same quarter in the prior year, the company posted $0.08 earnings per share. equities analysts predict that Vanda Pharmaceuticals Inc. will post -0.13 earnings per share for the current fiscal year.
In other news, SVP Gunther Birznieks sold 8,568 shares of the company’s stock in a transaction dated Tuesday, January 2nd. The stock was sold at an average price of $15.26, for a total value of $130,747.68. Following the completion of the transaction, the senior vice president now owns 118,366 shares of the company’s stock, valued at $1,806,265.16. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, insider Mihael Hristos Polymeropoulos sold 191,760 shares of the company’s stock in a transaction dated Tuesday, January 2nd. The stock was sold at an average price of $15.30, for a total value of $2,933,928.00. Following the completion of the transaction, the insider now directly owns 1,031,848 shares of the company’s stock, valued at approximately $15,787,274.40. The disclosure for this sale can be found here. In the last ninety days, insiders sold 287,506 shares of company stock valued at $4,665,795. Corporate insiders own 7.60% of the company’s stock.
TRADEMARK VIOLATION WARNING: “Vanda Pharmaceuticals Inc. (VNDA) Shares Bought by Macquarie Group Ltd.” was originally reported by The Lincolnian Online and is the property of of The Lincolnian Online. If you are reading this news story on another site, it was illegally stolen and republished in violation of United States and international trademark and copyright legislation. The original version of this news story can be read at https://www.thelincolnianonline.com/2018/03/21/vanda-pharmaceuticals-inc-vnda-shares-bought-by-macquarie-group-ltd.html.
About Vanda Pharmaceuticals
Vanda Pharmaceuticals Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies to address unmet medical needs. Its product portfolio includes HETLIOZ (tasimelteon), Fanapt (iloperidone), Tradipitant (VLY-686), Trichostatin A and AQW051. It offers HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24).
Receive News & Ratings for Vanda Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vanda Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.